---
title: "Understanding the Market | QYUNS-B rose over 11% during the session, its QX031N licensed to Roche; institutions say this transaction has certain rarity"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/263948377.md"
description: "QYUNS-B's stock price rose over 11% during intraday trading, and as of the time of writing, it has increased by 4.78%, reaching HKD 22.82, with a transaction volume of HKD 12.2938 million. The company has reached a global exclusive collaboration and licensing agreement with Roche, involving the long-acting self-immune dual antibody QX031N. QYUNS will receive a USD 75 million upfront payment and up to USD 995 million in milestone payments. Zhongyou Securities pointed out that this transaction demonstrates the clinical value and market potential of QX031N, which possesses a certain degree of rarity"
datetime: "2025-11-03T06:28:14.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/263948377.md)
  - [en](https://longbridge.com/en/news/263948377.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/263948377.md)
---

# Understanding the Market | QYUNS-B rose over 11% during the session, its QX031N licensed to Roche; institutions say this transaction has certain rarity

According to Zhitong Finance APP, QYUNS-B (02509) rose over 11% during the session, and as of the time of writing, it is up 4.78%, trading at HKD 22.82, with a transaction volume of HKD 12.2938 million.

In terms of news, on October 28, QYUNS announced that it has reached a global exclusive collaboration and licensing agreement with Roche for its independently developed long-acting dual antibody QX031N. According to the agreement, Roche will be granted global exclusive rights for the research, development, registration, production, and commercialization of QX031N. QYUNS will receive a USD 75 million upfront payment, as well as up to USD 995 million in milestone payments and potential future tiered royalties from product sales.

It is reported that QX031N injection is a long-acting dual antibody that simultaneously targets TSLP and IL-33. Zhongyou Securities pointed out that QX031N is in the preclinical pipeline and has reached a high upfront payment agreement with an MNC before entering the clinical stage. We believe this reflects the company's early innovation capabilities and also recognizes the market potential and target selection in the autoimmune respiratory track. From the perspective of the BD amount and the partner, this transaction has a certain rarity, and the clinical value of QX031N is not inferior to that of the TL1A dual antibody in the IBD field, which also means that this target combination has a leading position and market potential globally

### Related Stocks

- [02509.HK](https://longbridge.com/en/quote/02509.HK.md)

## Related News & Research

- [China's Bilibili Q1 revenue rises on advertising growth](https://longbridge.com/en/news/286892124.md)
- [Hesai sustains profitability as LiDAR shipments surge and secures Mercedes order](https://longbridge.com/en/news/286887280.md)
- [Xiaomi EV reportedly taps new battery suppliers for second brand to target EREV market](https://longbridge.com/en/news/286843996.md)
- [Key facts: Reliance-CATL talks on batteries; ₹131.58cr LOI Jamnagar G+12](https://longbridge.com/en/news/286842723.md)
- [Intel CEO says foundry business is gaining momentum as customer interest grows](https://longbridge.com/en/news/286826548.md)